Short chain fatty acids-producing and mucin-degrading intestinal bacteria predict the progression of early Parkinson’s disease

Nishiwaki, Hiroshi; Ito, Mikako; Hamaguchi, Tetsuya; Maeda, Tetsuya; Kashihara, Kenichi; Tsuboi, Yoshio; Ueyama, Jun; Yoshida, Takumi; Hanada, Hiroyuki; Takeuchi, Ichiro; Katsuno, Masahisa; Hirayama, Masaaki; Ohno, Kinji

doi:10.1038/s41531-022-00328-5

Cited by 61 publications

(48 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are more than 20 studies on gut microbiota in patients with PD and iRBD reported by us 19 – 22 and others 23 – 40 , but gut microbiota in DLB has not been reported to the best of our knowledge. We previously showed by meta-analysis of gut microbiota in different countries that mucin-degrading genus Akkermansia was increased in PD and iRBD, while short chain fatty acids (SCFA)-producing genera Faecalibacterium and Roseburia were decreased in PD but not in iRBD 20 , 21 .…”

Section: Introductionmentioning

confidence: 88%

Gut microbiota in dementia with Lewy bodies

Nishiwaki

Ueyama

Kashihara

et al. 2022

npj Parkinsons Dis.

Self Cite

View full text Add to dashboard Cite

Gut microbiota and fecal bile acids were analyzed in 278 patients with α-synucleinopathies, which were comprised of 28 patients with dementia with Lewy bodies (DLB), 224 patients with Parkinson’s disease (PD), and 26 patients with idiopathic rapid eye movement sleep behavior disorder (iRBD). Similarly to PD, short-chain fatty acids-producing genera were decreased in DLB. Additionally, Ruminococcus torques and Collinsella were increased in DLB, which were not changed in PD. Random forest models to differentiate DLB and PD showed that high Ruminococcus torques and high Collinsella, which presumably increase intestinal permeability, as well as low Bifidobacterium, which are also observed in Alzheimer’s disease, were predictive of DLB. As Ruminococcus torques and Collinsella are also major secondary bile acids-producing bacteria, we quantified fecal bile acids and found that the production of ursodeoxycholic acid (UDCA) was high in DLB. Increased UDCA in DLB may mitigate neuroinflammation at the substantia nigra, whereas neuroinflammation may not be critical at the neocortex. Theraeutic intervention to increase Bifidobacteirum and its metabolites may retard the development and progression of DLB.

show abstract

Section: Introductionmentioning

confidence: 88%

Gut microbiota in dementia with Lewy bodies

Nishiwaki

Ueyama

Kashihara

et al. 2022

npj Parkinsons Dis.

Self Cite

View full text Add to dashboard Cite

show abstract

“…In a recently published study, Nishiwaki and colleagues investigated the manner in which short-chain fatty acid-producing and mucin-degrading intestinal bacteria predict the progression of early PD [ 32 ]. They report that decreases in short-chain fatty acid-producing genera, Fusicatenibacter, Faecalibacterium and Blautia, as well as an increase of the mucin-degrading genus Akkermansia, predicted accelerated disease progression.…”

Section: Parkinson’s Diseasementioning

confidence: 99%

Gut Microbes and Neuropathology: Is There a Causal Nexus?

Dinan

2022

Pathogens

View full text Add to dashboard Cite

The gut microbiota is a virtual organ which produces a myriad of molecules that the brain and other organs require. Humans and microbes are in a symbiotic relationship, we feed the microbes, and in turn, they provide us with essential molecules. Bacteroidetes and Firmicutes phyla account for around 80% of the total human gut microbiota, and approximately 1000 species of bacteria have been identified in the human gut. In adults, the main factors influencing microbiota structure are diet, exercise, stress, disease and medications. In this narrative review, we explore the involvement of the gut microbiota in Parkinson’s disease, Alzheimer’s disease, multiple sclerosis and autism, as these are such high-prevalence disorders. We focus on preclinical studies that increase the understanding of disease pathophysiology. We examine the potential for targeting the gut microbiota in the development of novel therapies and the limitations of the currently published clinical studies. We conclude that while the field shows enormous promise, further large-scale studies are required if a causal link between these disorders and gut microbes is to be definitively established.

show abstract

“…1XD42-69, Eubacterium sp. 14 − 2, and Lachnospiraceae bacterium A4 (Morrison and Preston, 2016;Tamanai-Shacoori et al, 2017;Nishiwaki et al, 2020Nishiwaki et al, , 2022. On the other hand, Alistipes sp.…”

Section: Discussionmentioning

confidence: 99%

Lacticaseibacillus rhamnosus Probio-M9-driven mouse mammary tumor-inhibitory effect is accompanied by modulation of host gut microbiota, immunity, and serum metabolome

Kwok

Zhang

et al. 2022

Preprint

View full text Add to dashboard Cite

Breast cancer is one of the most common cancers in women. Gut microbiome may influence tumor growth and the outcome of cancer treatment, so it may be considered as a target for tumor prevention and treatment. This study investigated the preventive and therapeutic effects of the probiotic strain, Lacticaseibacillus rhamnosus Probio-M9 (Probio-M9), against mammary cancer in mice. Thirty-six female mice were randomly divided into three groups (n = 12 per group): control group (without tumor transplantation), model group (tumor transplantation; no probiotic administration), and probiotic group (30-day oral gavage of probiotic, started seven days before tumor transplantation). Changes in tumor size was recorded, and blood, tumor tissue, and stool samples were collected at the end of the trial for analysis. Significantly smaller tumor volume was observed in the probiotic group compared with the model group (P < 0.05). Probio-M9 significantly increased the Shannon diversity index of mouse fecal microbiota and modified the gut microbiota structure (P < 0.05), characterized by significantly more Alistipes sp., Porphyromonadaceae bacterium, and Bacteroidales bacterium (P < 0.05), compared with the model group. Additionally, Probio-M9 administration elevated the serum IFN-γ, IL-9, IL-13, and IL-27 levels, while reducing the serum levels of IL-5 (P < 0.05) and several metabolites (e.g., pyridoxal, nicotinic acid, 3-hydroxybutyric acid, glutamine; P < 0.05). These physiological changes might be associated with the protective effect of Probio-M9 against mammary tumor growth. Our results support that probiotic administration could be a means of harnessing host gut microbiome and other physiological responses in combating cancer.

show abstract

Short chain fatty acids-producing and mucin-degrading intestinal bacteria predict the progression of early Parkinson’s disease

Cited by 61 publications

References 74 publications

Gut microbiota in dementia with Lewy bodies

Gut microbiota in dementia with Lewy bodies

Gut Microbes and Neuropathology: Is There a Causal Nexus?

Lacticaseibacillus rhamnosus Probio-M9-driven mouse mammary tumor-inhibitory effect is accompanied by modulation of host gut microbiota, immunity, and serum metabolome

Contact Info

Product

Resources

About